NCT01870843View on ClinicalTrials.gov

A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom

PHASE4CompletedINTERVENTIONAL

Enrollment

261

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

Depressive Disorder, Major

Interventions

DRUG

Escitalopram

Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.

Trial Locations (10)

Unknown

Beijing

Guangzhou

Hangzhou

Hohhot

Jinan

Kunming

Nanjing

Shijiazhuang

Ürümqi

Xiamen

All Listed Sponsors

lead

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

NCT01870843 - A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom | Biotech Hunter | Biotech Hunter